Product Information
SUMATRIPTAN 5 MG NASAL SPRAY is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $17.0386 per EA under NDC 45802061906. Its NADAC has been published 304 times since Dec 9, 2020.
FDA first approved this application on Sep 21, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802061906
Classification
Generic
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTANApproval Type
Generic (ANDA)
FDA Application
ANDA213465FDA Approved
9/21/2020
TE Code
AB
On Market Since
10/4/2020
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN 5 MG NASAL SPRAY has been published 304 times since Dec 9, 2020, and over the history we have for it it has declined 65.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.0386 per EA |
|---|---|
| All-time high | $49.1328 (Dec 16, 2020) |
| All-time low | $17.0386 (Sep 23, 2026) |
| 52-week high | $22.5444 |
| 52-week low | $17.0386 |
| Median price | $31.7398 |
| Average price | $30.9805 |
| Largest weekly change | +44.0% (Aug 21, 2024) |
| Weeks tracked | 304 |
| Tracking since | Dec 9, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN 5 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN 5 MG NASAL SPRAY, manufactured by Padagis Israel Pharmaceuticals Ltd, is $17.0386 per EA (NDC 45802061906), effective Sep 30, 2026.
How has the price of SUMATRIPTAN 5 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN 5 MG NASAL SPRAY has declined 65.3%. It has been tracked across 304 weekly CMS publications since Dec 9, 2020.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN 5 MG NASAL SPRAY?
Since Dec 9, 2020, the NADAC for SUMATRIPTAN 5 MG NASAL SPRAY has ranged from a low of $17.0386 (Sep 23, 2026) to a high of $49.1328 (Dec 16, 2020), with a median of $31.7398 per EA.
Are there cheaper alternatives to SUMATRIPTAN 5 MG NASAL SPRAY?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SUMATRIPTAN 5 MG NASAL SPRAY in a comparable dosage form, but none are currently priced below it.
Who manufactures SUMATRIPTAN 5 MG NASAL SPRAY?
SUMATRIPTAN 5 MG NASAL SPRAY (NDC 45802061906) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.